{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:12:08Z","timestamp":1784344328563,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.recesp.2012.06.006","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T21:14:09Z","timestamp":1346966049000},"page":"901-910","source":"Crossref","is-referenced-by-count":67,"title":["An\u00e1lisis coste-efectividad de dabigatr\u00e1n para la prevenci\u00f3n de ictus y embolia sist\u00e9mica en fibrilaci\u00f3n auricular no valvular en Espa\u00f1a"],"prefix":"10.1016","volume":"65","author":[{"given":"Jos\u00e9 R.","family":"Gonz\u00e1lez-Juanatey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"\u00c1lvarez-Sabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Lobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Mart\u00ednez-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan C.","family":"Reverter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Gonz\u00e1lez-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.recesp.2012.06.006_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijcard.2010.08.042","article-title":"Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial Fibrillation in the Barbanza Area Study)","volume":"153","author":"Garc\u00eda-Castelo","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.recesp.2012.06.006_bib0010","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0300-8932(02)76733-X","article-title":"La fibrilaci\u00f3n auricular permanente en las enfermedades cardiovasculares en Espa\u00f1a. Estudio CARDIOTENS 1999","volume":"55","author":"Garc\u00eda-Acu\u00f1a","year":"2002","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.recesp.2012.06.006_bib0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1157\/13107118","article-title":"Prevalencia de fibrilaci\u00f3n auricular en la poblaci\u00f3n espa\u00f1ola de 60 o m\u00e1s a\u00f1os de edad. Estudio PREV-ICTUS","volume":"60","author":"Cea-Calvo","year":"2007","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.recesp.2012.06.006_bib0020","series-title":"Impacto sociosanitario de las enfermedades neurol\u00f3gicas en Espa\u00f1a. Informe FEEN","author":"S\u00e1nchez","year":"2006"},{"key":"10.1016\/j.recesp.2012.06.006_bib0025","first-page":"29","article-title":"Los costes de los cuidados informales asociados a enfermedades neurol\u00f3gicas discapacitantes de alta prevalencia en Espa\u00f1a","volume":"23","author":"Jorgensen","year":"2008","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.recesp.2012.06.006_bib0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/01.STR.0000153002.56324.8c","article-title":"Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?","volume":"36","author":"Miller","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.recesp.2012.06.006_bib0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000068743","article-title":"Atrial fibrillation is associated with severe acute ischemic stroke","volume":"22","author":"Dulli","year":"2003","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.recesp.2012.06.006_bib0040","first-page":"1","article-title":"Comparison of the impact of atrial fibrillation on the risk of early death after stroke in women versus men","volume":"20","author":"Roquer","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.recesp.2012.06.006_bib0045","first-page":"449","article-title":"Clinical features and prognosis of patients with chronic cerebrovascular disease (ICBAR study)","volume":"53","author":"Vidal-P\u00e9rez","year":"2011","journal-title":"Rev Neurol"},{"key":"10.1016\/j.recesp.2012.06.006_bib0050","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation .The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.recesp.2012.06.006_bib0055","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: The Task Force for the management of atrial fibrillation of the European Society of Cardiology","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.recesp.2012.06.006_bib0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.recesp.2012.06.006_bib0065","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/qjmed\/hcr092","article-title":"Challenges of stroke prevention in patients with atrial fibrillation in clinical practice","volume":"104","author":"Hobbs","year":"2011","journal-title":"QJM"},{"key":"10.1016\/j.recesp.2012.06.006_bib0070","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.recesp.2012.06.006_bib0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.18553\/jmcp.2009.15.3.244","article-title":"Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States","volume":"15","author":"Baker","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.recesp.2012.06.006_bib0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.amjmed.2011.03.013","article-title":"Stroke prevention in atrial fibrillation: current status and near-future directions","volume":"124","author":"De Caterina","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.recesp.2012.06.006_bib0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.recesp.2011.08.008","article-title":"Pacientes con fibrilaci\u00f3n auricular asistidos en consultas de atenci\u00f3n primaria. Estudio Val-FAAP","volume":"65","author":"Barrios","year":"2012","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.recesp.2012.06.006_bib0090","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.recesp.2012.06.006_bib0095","unstructured":"European Medicines Agency. European Public Assessment Report (EPAR) for Pradaxa [actualizado 23 Ago 2011]. Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000829\/human_med_000981.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.recesp.2012.06.006_bib0100","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.recesp.2012.06.006_bib0105","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.recesp.2012.06.006_bib0110","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ahj.2009.03.022","article-title":"Cost-effectiveness of warfarin: trial versus \u201creal-world\u201d stroke prevention in atrial fibrillation","volume":"157","author":"Sorensen","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.recesp.2012.06.006_bib0115","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1160\/TH11-02-0089","article-title":"Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective","volume":"105","author":"Sorensen","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.recesp.2012.06.006_bib0120","unstructured":"National Institute for Health and Clinical Excellence (NICE). Final Appraisal Determination. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. Disponible en: http:\/\/guidance.nice.org.uk\/TA\/Wave21\/10\/FAD\/FinalAppraisalDetermination\/pdf\/English"},{"key":"10.1016\/j.recesp.2012.06.006_bib0125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"Van Swieten","year":"1988","journal-title":"Stroke"},{"key":"10.1016\/j.recesp.2012.06.006_bib0130","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/14656566.2011.584063","article-title":"Anticoagulation prescription in atrial fibrillation","volume":"12","author":"Bertomeu-Gonz\u00e1lez","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.recesp.2012.06.006_bib0135","unstructured":"Instituto Nacional de Estad\u00edstica. Tasa de mortalidad de la poblaci\u00f3n de Espa\u00f1a a\u00f1o 2009. Disponible en: http:\/\/www.ine.es\/"},{"key":"10.1016\/j.recesp.2012.06.006_bib0140","unstructured":"Instituto Nacional de Estad\u00edstica. Indice de Precios de Consumo. Disponible en: http:\/\/www.ine.es\/"},{"key":"10.1016\/j.recesp.2012.06.006_bib0145","unstructured":"Ministerio de Sanidad, Pol\u00edtica Social e Igualdad. Nom\u00e9nclator DIGITALIS-INTEGRA. Marzo 2011. Disponible en: http:\/\/www.msc.es\/profesionales\/farmacia\/nomenclatorDI.htm"},{"key":"10.1016\/j.recesp.2012.06.006_bib0150","unstructured":"Real Decreto-ley 8\/2010. BOE de 24 de mayo de 2010:126. Disponible en: http:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010-8228.pdf"},{"key":"10.1016\/j.recesp.2012.06.006_bib0155","unstructured":"Ministerio de Sanidad, Pol\u00edtica Social e Igualdad. An\u00e1lisis y desarrollo de los GDR en el Sistema Nacional de Salud. Disponible en: http:\/\/www.msc.es\/estadEstudios\/estadisticas\/inforRecopilaciones\/anaDesarrolloGDR.htm"},{"key":"10.1016\/j.recesp.2012.06.006_bib0160","unstructured":"Oblikue Consulting. Base de datos sanitarios eSalud. Disponible en: http:\/\/www.oblikue.com\/bddcostes\/"},{"key":"10.1016\/j.recesp.2012.06.006_bib0165","series-title":"Coagul\u00f3metros port\u00e1tiles. Revisi\u00f3n de la evidencia cient\u00edfica y evaluaci\u00f3n econ\u00f3mica de su uso en el autocontrol del tratamiento anticoagulante oral","author":"de Sol\u00e0-Morales Serra","year":"2003"},{"key":"10.1016\/j.recesp.2012.06.006_bib0170","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1157\/13113927","article-title":"Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral","volume":"60","author":"Navarro","year":"2007","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.recesp.2012.06.006_bib0175","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.recesp.2012.06.006_bib0180","first-page":"518","article-title":"Costs deriving from strokes from a social perspective. A retrospective incidence approach with a follow-up at three years","volume":"43","author":"Hervas-Angulo","year":"2006","journal-title":"Rev Neurol"},{"issue":"Espec Congr 1","key":"10.1016\/j.recesp.2012.06.006_bib0185","first-page":"1","article-title":"Cuidados informales asociados a la limitaci\u00f3n de la autonom\u00eda en supervivientes a accidentes cerebrovasculares","volume":"25","author":"Hidalgo","year":"2011","journal-title":"Gac Sanit"},{"key":"10.1016\/j.recesp.2012.06.006_bib0190","unstructured":"Jim\u00e9nez-Mart\u00edn S, Oliva J, Vilaplana Prieto C. Sanidad y dependencia, matrimonio o divorcio: atenci\u00f3n sanitaria y servicios sociales, \u00bfuna cuesti\u00f3n de integraci\u00f3n o s\u00f3lo de coordinaci\u00f3n? Madrid: C\u00edrculo de la Sanidad; 2011. Disponible en: http:\/\/www.circulodelasanidad.com\/documentos\/sanidadydependencia.pdf"},{"key":"10.1016\/j.recesp.2012.06.006_bib0195","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","article-title":"\u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a?","volume":"16","author":"Sacrist\u00e1n","year":"2002","journal-title":"Gac Sanit"},{"key":"10.1016\/j.recesp.2012.06.006_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.recesp.2012.06.006_bib0205","doi-asserted-by":"crossref","first-page":"d6333","DOI":"10.1136\/bmj.d6333","article-title":"Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit harm and economic analyses","volume":"343","author":"Pink","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.recesp.2012.06.006_bib0210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/heartjnl-2011-300646","article-title":"Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation","volume":"98","author":"Kansal","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.recesp.2012.06.006_bib0215","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","article-title":"Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation","volume":"123","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.recesp.2012.06.006_bib0220","doi-asserted-by":"crossref","first-page":"570","DOI":"10.7326\/0003-4819-154-8-201104190-00014","article-title":"Revised dabigatran base-case cost-effectiveness estimates and comment responses","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.recesp.2012.06.006_bib0225","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1161\/STROKEAHA.111.641027","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack","volume":"43","author":"Kamel","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.recesp.2012.06.006_bib0230","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3111\/13696998.2012.673525","article-title":"Cost-effectiveness of dabigatr\u00e1n etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark","volume":"15","author":"Langkilde","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.recesp.2012.06.006_bib0235","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"1987"},{"key":"10.1016\/j.recesp.2012.06.006_bib0240","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/STROKEAHA.110.584557","article-title":"Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation","volume":"41","author":"Schwartz","year":"2010","journal-title":"Stroke"}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300893212003855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300893212003855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T11:55:37Z","timestamp":1643370937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300893212003855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0300893212003855"],"URL":"https:\/\/doi.org\/10.1016\/j.recesp.2012.06.006","relation":{},"ISSN":["0300-8932"],"issn-type":[{"value":"0300-8932","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}